Previous close | 122.30 |
Open | 125.35 |
Bid | 125.25 x 0 |
Ask | 125.70 x 0 |
Day's range | 125.35 - 125.35 |
52-week range | 113.00 - 138.75 |
Volume | |
Avg. volume | 17 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
WILMINGTON, Del., March 25, 2024--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1
Shares of Super Micro (SMCI) are trading lower Tuesday morning as the company moves to sell 2 million shares of its common stock in a public offering. Goldman Sachs will be the sole underwriter of the proposed offering and is expected to have a 30-day option to purchase up to 300,000 additional shares. Shares of Chinese EV maker XPeng (9868.HK) are moving as the company released its fourth quarter report. The report showed a quarterly revenue of $1.84 billion, which is an increase of 153.9% from the same period in 2022. AstraZeneca (AZN) has announced it will buy the drug developer Fusion Pharmaceuticals (FUSN) in a deal valued at around $2 billion. Shares of Fusion are surging on Tuesday morning in response to the announcement. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Nicholas Jacobino
WILMINGTON, Del., March 19, 2024--AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.